Intelligence · Clinical Pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
- Programs
- 2,640
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 199 programs
- George Institute for 119 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
-
Selinexor
Karyopharm Therapeutics Inc
Breast Cancer
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Carcinoma, Neuroendocrine
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Diffuse Large B-cell Lymphoma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Leukemia
2 trials -
Selinexor
Karyopharm Therapeutics Inc
Locally Advanced Unresectable or Metastatic Melanoma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Metastatic Colorectal Cancer
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Non-small Cell Lung Cancer
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Ovarian Carcinoma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Peripheral T-cell Lymphoma (PTCL)
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Prostate Cancer
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Recurrent Small Cell Lung Carcinoma
1 trial -
Selinexor (KPT-330)
Karyopharm Therapeutics Inc
Squamous Cell Carcinoma
1 trial -
Selinexor 100 mg
Karyopharm Therapeutics Inc
Non-Small Cell Lung Carcinoma (NSCLC)
1 trial -
Selpercatinib
Eli Lilly and Company
Medullary Thyroid Cancer
1 trial -
Selpercatinib Monotherapy
United Therapeutics Europe Ltd
Differentiated Thyroid Cancer
1 trial -
Selumetinib
United Therapeutics Europe Ltd
Metastatic Thyroid Gland Carcinoma
1 trial -
Selumetinib
United Therapeutics Europe Ltd
Malignant Peripheral Nerve Sheath Tumors
1 trial -
Serplulimab
The First People's Hospital of Lianyungang
Colorectal Cancer (Diagnosis)
1 trial -
Serplulimab
The First People's Hospital of Lianyungang
HER2-positive Gastric Cancer
1 trial -
Serplulimab
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients (POP-Durva)
The George Institute
Untreated small triple negative breast cancer
1 trial -
Sigvotatug vedotin, PF-08634404
Pfizer Australia Pty Ltd
Advanced Solid Tumors
1 trial -
Sindillimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Sintilimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Neoplasms
1 trial -
Sintilimab
The First People's Hospital of Lianyungang
Carcinoma
1 trial -
Sintilimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Sintilimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Renal Cell Carcinoma
1 trial -
Sintilimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer Stage III
1 trial -
Sintilimab
The First People's Hospital of Lianyungang
Multiple Primary Lung Cancer
1 trial -
Sintilimab
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma (NPC)
1 trial -
Sintilimab
The First People's Hospital of Lianyungang
Ovarian Clear Cell Carcinoma
1 trial -
Sintilimab
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Sintilimab
The First People's Hospital of Lianyungang
Small Cell Lung Cancer Limited Stage
1 trial -
Sintilimab (approved)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma (HCC)
1 trial -
Sintilimab Combined with Platinum-containing Chemotherapy
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
Sintilimab in combination with Multimodality Radiotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Sintilimab injection plus Inlyta treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Carcinoma, Renal Cell
1 trial -
Sintilimab with Interleukin-2+CAPOX
The First People's Hospital of Lianyungang
Locally Advanced Rectal Adenocarcinoma
1 trial -
Sintilimab,nab-paclitaxel and tegio
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
Sitravatinib
BeiGene
Carcinoma, Hepatocellular
1 trial -
Sitravatinib, Tislelizumab, Sitravatinib
Disc Medicine
Uveal melanoma
1 trial -
Sm-EDTMP
Jazz Pharmaceuticals Ireland Limited
Metastatic Osteosarcoma
1 trial -
Sodium Cridanimod
Xenetic Biosciences
Endometrial Cancer
1 trial -
SonoVue 8 microlitres/mL powder and solvent for dispersion for injection, CARBOPLATIN
Pari Pharma GmbH
recurrent primary supratentorial malignant brain tumors in children
1 trial -
Sorafenib
United Therapeutics Europe Ltd
Lung Cancer
1 trial -
Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin
Bayer HealthCare AG
Carcinoma, Hepatocellular
1 trial -
Steroids switch
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
Stivarga 40 mg film-coated tablets
Ningbo Cancer Hospital
Bone sarcoma
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,640 programs match both the therapeutic area and stage filters in our published index.
Data attribution: Data sources · All pipeline programs